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Introduction: Mutations in the epidermal growth factor receptor
(EGFR) kinase domain such as EGFR-L858R and EGFR-G719S
have been reported to activate the kinase and also sensitize a subset
of patients with non-small cell lung cancer to EGFR kinase inhibitor
treatment. Nevertheless, for other common point mutations such as
EGFR-L861Q, it is unclear whether and to what extent they sensitize
toward gefitinib and erlotinib. Thus far, there is no reliable cellular
assay to compare in a ligand-independent manner intrinsic kinase
activity and drug sensitivity of the unmutated (wild type) and
mutated EGFR kinase domain.
Methods: To overcome this obstacle, we introduced L858R, G719S,
and L861Q into the backbone of EGFRvIII. EGFRvIII has a wild
type-kinase domain but is activated in a ligand-independent manner
through a deletion in the extracellular domain.
Results: Using this tool, we show that the L861Q mutation displays
enhanced kinase activity and transforming potential compared with
L858R, G719S, and also to the wild type-EGFR kinase domain.
Interestingly, L861Q does not increase drug sensitivity toward
clinically used EGFR kinase inhibitors in contrast to the L858R and
G719S mutation. In addition, we demonstrate that EGFR-L861Q
could be effectively inhibited with the irreversible second-genera-
tion EGFR inhibitor WZ-4002.
Conclusions: Thus, in the common EGFR-L861Q mutation, acti-
vation of the kinase domain is uncoupled from a sensitizing effect
toward clinically approved kinase inhibitors. Therefore, patients
with EGFR-L861Q may not have the same clinical benefit from
gefitinib/erlotinib treatment as patients with EGFR-L858R and
EGFR-G719S mutations. Treatment with irreversible second-gener-
ation kinase inhibitors such as WZ-4002 may be an attractive option
in the future for patients with EGFR-L861Q.
Key Words: EGFR, Kinase activity, Gefitinib, Erlotinib, Drug
sensitivity.
(J Thorac Oncol. 2011;6: 387–392)
A subset of patients with non-small cell lung cancer(NSCLC) with activating mutations in the epidermal
growth factor receptor (EGFR) kinase domain was shown to
respond to targeted therapy.1 Nevertheless, not all mutations
in the EGFR kinase domain are activating and/or are drug
sensitive.2–5 Recently, we have established a comprehensive
profile of kinase activity, transforming ability, and drug
sensitivity of a panel of EGFR kinase domain mutations.5 We
have shown that mutations L858R and G719S are very
sensitive to all the drugs tested, whereas another common
mutation L861Q is relatively insensitive towards inhibitor
treatment.5 This is in agreement with a previous report.6
So far, it was not possible to compare the drug sensi-
tivity of ligand-independent mutant EGFR with that of EGF-
dependent wild-type EGFR in a ligand-independent cellular
assay.7 Thus, we aimed to establish a cell-based system to
compare the drug sensitivities of wild type (wt) and mutant
receptor kinase domains.
EGFRvIII is an active oncogenic kinase, which is
frequently found in glioblastoma patients.8 EGFRvIII lacks
part of the extracellular ligand-binding domain leading to
constitutive, ligand-independent activation.8 In a recent re-
port, we have successfully used EGFRvIII to demonstrate
that certain EGFR mutants that were reported in patients with
NSCLC in fact are kinase dead.5 Because EGFRvIII contains
a wt-kinase domain and does not require ligand for activation,
it can be used as test backbone to study the effect of
mutations on kinase activity and inhibitor sensitivity in cells
in a ligand-independent manner.5 Using this system in this
study, we compared the kinase activity and transforming
ability of common EGFR mutations.
MATERIALS AND METHODS
Constructs, Cell Lines, and Reagents
Cloning of MiGR1-EGFRvIII was described previously.5
Point mutations were introduced into MiGR1-EGFRvIII using
the Quickchange Site-Directed Mutagenesis kit (Fermentas, St.
Leon-Rot, Germany) and confirmed by sequencing. HEK293
cells were cultured in Dulbecco’s Modified Eagle Medium
(PAA, Pasching, Austria) supplemented with 10% fetal calf
serum (PAA). Ba/F3 cells were cultured in Roswell Park Me-
morial Institute 1640 (Life Technologies) supplemented with
interleukin-3 (IL-3; R&D, Wiesbaden, Germany). Stable Ba/F3
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FIGURE 1. EGFRvIII-based assay identifies L861Q as hyperactive kinase with strongest oncogenic potential. A, Clinically rele-
vant point mutations in EGFRvIII backbone were transiently overexpressed in HEK293 cells and analyzed for autokinase activity
and Stat5 activation. B, Comparative activation of EGFR and Stat5 was quantified and plotted as fold increase in activity with
respect to wild type. Analysis was done in triplicates, and measured “p values” were shown. C, Ba/F3 cells stably expressing
EGFRvIII mutants were tested for their ability to outgrow untransduced cells on IL-3 withdrawal. Percentage of eGFP-positive
cells was measured in triplicates at indicated time points by FACS analysis. D, NIH/3T3 cells stably expressing wild-type or mu-
tant EGFRvIII were plated in soft agar assay at a density of 2.5  104 cells/well in triplicates in a six-well plate. Three weeks
after plating, colonies were stained with MTT solution and counted. E, Average number of colonies for each cell line was
shown. EGFR, epidermal growth factor receptor; IL, interleukin; eGFP, enhanced green fluorescent protein; FACS, fluorescence
activated cell sorting; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide.
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cell lines were established by retroviral infection with MiGR1-
EGFRvIII constructs followed by IL-3 withdrawal. Gefitinib
was provided by AstraZeneca, and AEE 788 was a kind gift
from Novartis Pharma. Erlotinib was purchased from pharmacy.
WZ-4002 was purchased from Axon Medchem BV. Each com-
pound was dissolved in dimethyl sulfoxide to make an initial
stock solution of 10 mmol/liter (gefitinib, AEE 788 and WZ-
4002) and 2.5 mmol/liter (erlotinib).
FIGURE 2. EGFR-L861Q is not a drug-sensitizing mutation unlike L858R and G719S. Stable Ba/F3 cell lines expressing wild-
type or mutant EGFRvIII were tested for their sensitivity toward (A) gefitinib, (B) erlotinib, and (C) AEE788 at indicated concen-
trations. D, Table representing the effect of individual mutations on intrinsic properties of the kinase. E, Ba/F3 cells expressing
wild-type or mutant EGFRvIII were treated with increasing concentrations (50, 100, 250, 500, or 1000 nM) of gefitinib or er-
lotinib for 30 minutes and analyzed for the inhibition of EGFR autophosphorylation and Stat5 phosphorylation. EGFR, epider-
mal growth factor receptor.
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Proliferation Assay, Soft Agar Assay, and
Western Blotting
For proliferation analysis, Ba/F3-EGFRvIII cells (1 
104) were plated into 96-well plates, and inhibitors were
added at indicated concentrations. Cell proliferation was
measured at 48 hours using CellTiter96 Proliferation Assay
(Promega, Madison, WI).
To test anchorage-independent growth in soft agar, 1
ml of 0.75% agar (Difco, Lawrence, KS) solution in Iscove’s
Modified Dulbecco’s Medium (Life Technologies) was first
placed as a bottom layer in six-well plates; 2.5  104 cells
were seeded in 3 ml containing 0.3% agar. Colonies were
stained with 3-(4,5-dimethyl-2-thiazolyl)-2.5-diphenyl-2H-
tetrazolium bromide (Sigma, Taufkirchen, Germany) and
counted.
HEK293 cells were transiently transfected with wild-
type or mutant MiGR1/EGFRvIII using Lipofectamine 2000
reagent. Cell lysates were prepared for biochemical analysis.
Cell lysates of stable Ba/F3 cell lines expressing wild-type or
mutant EGFRvIII were prepared after treatment with inhibi-
tors at indicated concentrations for 30 minutes. Cells lysis,
sodium dodecyl sulfate polyacrylamide gel electrophoresis,
and Western blotting were performed as described previously.5
Following antibodies were used for analysis: phosphorylated
EGFR-Tyr1068 (Cell Signaling, Danvers, MA), p-EGFR-Tyr845
(Santa Cruz Biotechnoloy, Heidelberg, Germany), EGFR (Santa
Cruz Biotechnology), pStat5-Tyr694 (Cell Signaling), Stat5
(Santa Cruz Biotechnology), pAkt-Ser473 (Cell Signaling), and
Akt1/2 (Santa Cruz Biotechnology). Blots were scanned and
subjected to analysis using ImageJ software.
RESULTS AND DISCUSSION
The most common point mutations reported in patients
with NSCLC, EGFR-L858R, EGFR-G719S, and EGFR-
L861Q, were selected for this study. Our aim was to deter-
mine kinase activity and transforming potential of these
mutants compared with the wt-EGFR kinase domain. Using
the wt EGFR as reference has several limitations: ligand
stimulation and the required serum starvation of cells may
alter cellular responses. In addition, the wt receptor cannot be
used as comparison for the transforming potential of certain
EGFR mutants. The use of EGFRvIII as reference abrogates
several of these limitations. EGFRvIII contains a wt-kinase
domain and, thus, can be used to study the impact of muta-
tions on the kinase activity in an unaltered cellular setting.
Therefore, we first cloned all three point mutations into
the EGFRvIII backbone. For analysis of kinase activity and
signaling, we chose HEK293 cells, which lack endogenous
EGFR.5,9 Both EGFRvIII-G719S and EGFRvIII-L858R
showed a two- to four-fold increased autophosphorylation
compared with EGFRvIII containing a wt-kinase domain
(Figures 1A, B). EGFRvIII-L861Q showed the strongest au-
tophosphorylation, which was more than 10-fold higher than
EGFRvIII (Figures 1A, B). This data are in agreement with
studies using the wt-EGFR receptor with ligand stimulation.10
EGFRvIII-L861Q was also the strongest activator of Stat5
indicating that not only autophosphorylation but also sub-
strate phosphorylation is enhanced by this mutation. None of
the EGFRvIII constructs increased Akt activity above levels
observed under normal serum conditions (Figure 1A).
To compare the transforming abilities of these mutants,
we performed a competitive growth assay, in which the
outgrowth of oncogene-transduced cells under growth factor
withdrawal in a mixed population is measured. To this end,
newly transduced (transduction efficiency20%), unselected
stable Ba/F3 cell lines expressing EGFRvIII mutants together
with enhanced green fluorescent protein were deprived of
IL-3. Outgrowth of enhanced green fluorescent protein-pos-
itive cells was measured by fluorescence activated cell sorting
analysis over time. EGFRvIII-L861Q expressing cells
showed the strongest proliferation advantage in this compe-
tition assay (Figure 1C). EGFRvIII-G719S and EGFRvIII-
L858R expressing cells were also selected more efficiently
than cells expressing unmutated EGFRvIII (Figure 1C). After
prolonged IL-3 deprivation, however, all EGFRvIII con-
structs finally conferred IL-3 independent growth. Thus, mu-
tation L861Q leads to the strongest gain in kinase activity and
most rapid induction of cytokine independent growth com-
pared with the wt-kinase domain. To test the transforming
potential of EGFRvIII-based mutants in an independent as-
say, NIH/3T3 cells were transduced with wild-type or mutant
EGFRvIII kinase, and stable cell lines were used for a soft
agar assay. EGFRvIII with wild-type kinase induced anchor-
age- and growth factor-independent colony formation,
whereas no colonies were detected in untransduced or vector-
transduced cells (Figures 1D, E). Moreover, cells expressing
EGFRvIII  G719S, EGFRvIII  L858R, and EGFRvIII 
L861Q formed higher numbers of colonies compared with
cells expressing unmutated EGFRvIII kinase (Figures 1D, E).
We then determined the effect of oncogenic EGFR
kinase domain mutations on drug sensitivity. We used stably
transduced Ba/F3 cell lines expressing wild-type or mutant
EGFRvIII and the EGFR kinase inhibitors gefitinib, erlotinib,
and AEE788. Gefitinib and erlotinib are selective EGFR
inhibitors already approved in the clinic. AEE788 is a com-
pound in development inhibiting both EGFR and Her2.
EGFRvIII-L858R expressing cells were very sensitive to all
drugs tested with an half maximal inhibitory concentration
(IC50) value of less than 50 nM (Figures 2A–C). EGFRvIII-
G719S expressing cells displayed an intermediate sensitivity.
Both mutations led to lower IC50 values compared with
wild-type EGFRvIII, thus sensitizing cells to EGFR kinase
inhibitors (Table 1). In contrast, EGFRvIII-L861Q expressing
cells displayed IC50 values identical to wt EGFRvIII (Figures
2A–C). Although this mutation induced the strongest prolif-
TABLE 1. IC50 Values (nM) of Wild-Type and Mutant
EGFRvIII Kinases against Gefitinib, Erlotinib, AEE788, and
WZ-4002 Calculated from Figures 2 and 3
Mutations Gefitinib Erlotinib AEE788 WZ-4002
EGFRvIII 498 409 198 138
EGFRvIII  G719S 155 57 17 66
EGFRvIII  L858R 55 16 10 10
EGFRvIII  L861Q 458 366 160 74
EGFR, epidermal growth factor receptor.
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eration advantage and highest increase in kinase activity
among all mutations tested, it did not lead to enhanced kinase
inhibitor sensitivity (Figure 2D). Western blot analysis after
treatment of Ba/F3 cells expressing EGFRvIII constructs with
gefitinib or erlotinib showed that EGFRvIII-G719S and
EGFRvIII-L858R but not EGFRvIII-L861Q displayed en-
hanced inhibition of downstream Stat5 signaling compared
with the wild-type EGFRvIII (Figure 2E). Thus, in this
common EGFR mutation, activation of the kinase domain
seems to be uncoupled from sensitizing effects toward kinase
inhibitors. In a recent report, L858R and G719S mutants were
shown to have a reduced binding affinity toward adenosine
triphosphate compared with wild-type EGFR, making them
more accessible for ATP competitive EGFR inhibitors.11
In contrast, EGFR-L861Q was demonstrated to retain high
binding affinity for ATP.12 This may explain the lack of
enhanced sensitivity toward reversible inhibitors of this
mutant. Thus, these results suggest that NSCLC patients
FIGURE 3. EGFR-L861Q is more sensitive to WZ-4002 compared with wild-type EGFRvIII. A, Ba/F3 cells stably expressing
either wild-type or mutant EGFRvIII were treated with the indicated concentrations of WZ-4002 for 48 hours and tested for
cell proliferation inhibition. B, Wild-type or mutant Ba/F3-EGFRvIII cell lines were treated with increasing concentrations of
WZ-4002 (50, 100, 25, 500, or 1000 nM) for 30 minutes and analyzed for inhibition of EGFR, Stat5, and extracellular signal-
regulated kinase 1/2 phosphorylation. EGFR, epidermal growth factor receptor.
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with the EGFR-L861Q mutation may not benefit as much
from EGFR inhibitor treatment with gefitinib or erlotinib
as patients with the EGFR-L858R, EGFR-G719S, or
EGFR exon 19 deletions.
Variation in drug response toward different activating
mutations in oncogenic tyrosine kinases has been reported in
various cancers, and accumulating evidence indicates that
this may have impact on the clinical outcome on inhibitor
treatment.13 Therefore, it may be beneficial to test alternative
EGFR inhibitors toward less sensitive activating EGFR mu-
tations such as EGFR-L861Q. WZ-4002 is a novel irrevers-
ible inhibitor of EGFR kinase that was recently shown to
have significant activity both in vitro and in vivo.14 Both
EGFRvIII-L858R and EGFRvIII-G719S showed lower IC50
values toward WZ-4002 treatment compared with wild-type
EGFRvIII (Figure 3, Table 1). Interestingly, EGFRvIII-
L861Q also showed significantly more sensitivity against
WZ-4002 compared with wild-type EGFRvIII (Figure 3,
Table 1). WZ-4002 is an irreversible inhibitor and binds to
the active conformation of the EGFR kinase.14 Because all
mutations tested in this study are activating, they may be
more sensitive to WZ-4002. Therefore, irreversible second-
generation kinase inhibitors such as WZ-4002 may offer a
more potent alternative treatment for patients with the EGFR-
L861Q mutation in the future.15 The Ba/F3-EGFRvIII-based
system described in this report will be a valuable tool to test
novel compounds and strategies.
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